Fragment-Based Drug Discovery: Difference between revisions
No edit summary |
No edit summary |
||
| Line 28: | Line 28: | ||
<scene name='Sandbox_reserved_394/Compound_1/1'>Compound 1</scene> actually consists of two ligands: a <scene name='Sandbox_reserved_394/Compound_1/2'>fluorobiphenyl-based ligand</scene> and a <scene name='Sandbox_reserved_394/Compound_1/3'>naphthalene derivative</scene>. | <scene name='Sandbox_reserved_394/Compound_1/1'>Compound 1</scene> actually consists of two ligands: a <scene name='Sandbox_reserved_394/Compound_1/2'>fluorobiphenyl-based ligand</scene> and a <scene name='Sandbox_reserved_394/Compound_1/3'>naphthalene derivative</scene>. | ||
<scene name='Sandbox_reserved_394/ | <scene name='Sandbox_reserved_394/Compound_2/1'>Compound 2</scene> is an acylsulfonamide-based ligand. | ||
<scene name='Sandbox_reserved_394/Compound_3/1'>Compound 3</scene> is a nitrobenzenesulfonamide-based ligand. | <scene name='Sandbox_reserved_394/Compound_3/1'>Compound 3</scene> is a nitrobenzenesulfonamide-based ligand. | ||